Pharmacological therapy for atrial fibrillation: current options and new agents

Bibliography

• Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics – 2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation2006;113:e85-151
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation2004;110:1042-6
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation1998;98:946-52
   PubMed Web of Science ®Google Scholar
• Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J1959;58:59-70
   PubMed Web of Science ®Google Scholar
• Nattel S. New ideas about atrial fibrillation 50 years on. Nature2002;415:219-26
   PubMed Web of Science ®Google Scholar
• Allessie M, Ammers WJEP, Bonke FIM, et al. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. In: Zipes DP, Jalife J, editors, Cardiac electrophysiology and arrhythmia. Grune and Stratton: New York, 1985. p. 265-75
   Google Scholar
• Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med1998;339:659-66
   PubMed Web of Science ®Google Scholar
• Levy S, Camm AJ, Saksena S, et al. International consensus on nomenclature and classification of atrial fibrillation: a collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of pacing and electrophysiology. J Cardiovasc Electrophysiol2003;14:443-5
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén L, Cannom D et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol2006;48(4):e149-246.
   Web of Science ®Google Scholar
• Patton KK, Zacks ES, Chang JY, et al. Clinical subtypes of lone atrial fibrillation. Pacing Clin Electrophysiol2005;28:630-8
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation1997;96:1180-4
   PubMed Web of Science ®Google Scholar
• Gaborit N, Steenman M, Lamirault G, et al. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation2005;112:471-81
   PubMed Web of Science ®Google Scholar
• Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation1995;92:1954-68
   PubMed Web of Science ®Google Scholar
• Shiroshita-Takeshita A, Brundel BJJM, Nattel S. Atrial fibrillation: basic mechanisms, remodeling, and triggers. J Interv Card Electrophysiol2005;13:181-93
   PubMed Web of Science ®Google Scholar
• Spach J, Josephson M. Initiating reentry: the role of nonuniform anisotropy in small circuits. J Cardiovasc Electrophysiol1994;5:182-209
   PubMed Web of Science ®Google Scholar
• Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol2008;51:802-9
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet2007;369:1208-19
   PubMed Web of Science ®Google Scholar
• Korantzopoulos P, Kolettis T, Siogas K, et al. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit2003;9:RA225-9
   PubMedGoogle Scholar
• Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation2001;104:174-80
   PubMed Web of Science ®Google Scholar
• Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med1997;336:905-11
   PubMed Web of Science ®Google Scholar
• Ellinor PT, Shin JT, Moore RK, et al. Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation2003;107:2880-3
   PubMed Web of Science ®Google Scholar
• Roberts R. Genomics and cardiac arrhythmias. J Am Coll Cardiol2006;47:9-21
   PubMed Web of Science ®Google Scholar
• Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet2006;15:2185-91
   PubMed Web of Science ®Google Scholar
• Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med2006;354:2677-88
   PubMed Web of Science ®Google Scholar
• Firouzi M, Ramanna H, Kok B, et al. Association of human connexin 40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ Res2004;95:e29-33
   PubMed Web of Science ®Google Scholar
• Juang JM, Chern YR, Tsai CT, et al. The association of human connexin 40 genetic polymorphisms with atrial fibrillation. Int J Cardiol2007;116:107-12 [Epub 2006 Jun 30]
   PubMed Web of Science ®Google Scholar
• Tsai CT, Lai LP, Lin JL, et al. Renin-Angiotensin system gene polymorphisms and atrial fibrillation. Circulation2004;109:1640-6
   PubMed Web of Science ®Google Scholar
• Ravn LS, Hofman-Bang J, Dixen U, et al. Relation of 97T polymorphism in KCNE5 to risk of atrial fibrillation. Am J Cardiol2005;96:405-7
   PubMed Web of Science ®Google Scholar
• Lai LP, Su MJ, Yeh HM, et al. Association of the human minK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation. Am Heart J2002;114:485-90
   Web of Science ®Google Scholar
• The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators: a comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med2002;347:1825-33
   PubMed Web of Science ®Google Scholar
• The AFFIRM investigators: relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of rhythm management (AFFIRM) study. Circulation2004;109:1509-13
   PubMed Web of Science ®Google Scholar
• Pedersen O, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation2001;104:292-6
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S, et al., for the AF-CHF Investigators: Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med2008;358:2667-77
   PubMed Web of Science ®Google Scholar
• Vaughan Williams E. Classification of antiarrhythmic actions. In: Vaughan Williams E, editor, Handbook of experimental pharmacology: antiarrhythmic drugs. Berlin: Springer Verlag, 1989. p. 45-67
   Google Scholar
• The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation1991;84:1831-51
   PubMed Web of Science ®Google Scholar
• The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med1989;321:406-12
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med1999;341:857-65
   PubMed Web of Science ®Google Scholar
• Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med2006;166:719-28
   PubMed Web of Science ®Google Scholar
• Pritchett EL, Page RL, Connolly SJ, et al. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose response. J Am Coll Cardiol2000;36:794-802
   PubMed Web of Science ®Google Scholar
• Page RL, Connolly SJ, Wilkinson WE, et al. Azimilide supraventricular arrhythmia Program (ASAP) investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. Am Heart J2002;143:643-9
   PubMed Web of Science ®Google Scholar
• Camm AJ, Pratt CM, Schwartz PJ, et al. On behalf of the Azimilide post-infarct survival evaluation (ALIVE) Investigators. Mortality in patients with recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation2004;109:990-6
   PubMed Web of Science ®Google Scholar
• Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation2004;110:3646-54
   PubMed Web of Science ®Google Scholar
• Kerr CR, Connolly SJ, Kowey P, et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol2006;98:215-18
   PubMed Web of Science ®Google Scholar
• Lombardi F, Borggrefe M, Ruzyllo W, et al., for the A-COMET-II Investigators. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-Cardioversion Maintenance Trial-II) trial. Eur Heart J2006;27:2224-31
   PubMed Web of Science ®Google Scholar
• Page RL, Pritchett EL, Connolly S, Wilkinson WE. for the SVA-4 Investigators. Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. J Cardiovasc Electrophysiol2008;19:172-7
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Dorian P, Straub M, et al. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent onset atrial fibrillation or atrial flutter. J Am Coll Cardiol2004;44:99-104
   PubMed Web of Science ®Google Scholar
• Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm-and rate-controlling effects. J Cardiovasc Electrophysiol2006;17:S17-20
   PubMed Web of Science ®Google Scholar
• Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J2003;24:1481-7
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med2007;357:987-99
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J2008;156:527.e1-527.e9
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med2008;358:2678-87
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Connolly SJ, Crijns HJ, et al. Rationale and design of ATHENA: a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol2008;19:69-73
   PubMed Web of Science ®Google Scholar
• Kowey PR, Aliot EM, Capucci A, et al. Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter [abstract]. Heart Rhythm2007;4:S72
   Google Scholar
• Arya A, Silberbauer J, Sulke N, Camm AJ. A phase 2 pilot study of the efficacy of ATI-2042 in subjects with paroxysmal atrial fibrillation and implanted pacemakers [abstract]. Heart Rhythm2006;3:S164
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. A trial to determine the relative effect of PM101 i.v. versus placebo on hemodynamics in healthy adult volunteers. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00502346 (last updated 22 August 2008).
   Google Scholar
• Vest JA, Wehrens XH, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation2005;111:2025-32
   PubMed Web of Science ®Google Scholar
• Kumagai K, Nakashima H, Gondo N, Saku K. Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol2003;14:880-4
   PubMed Web of Science ®Google Scholar
• Roy D, Rowe BH, Stiell IG, et al., for the CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel antiarrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol2004;44:2355-61
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation2008;117:1518-25
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Juul-Moller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized placebo-controlled, multicenter trial [abstract]. J Am Coll Cardiol2006;47:10A
   Google Scholar
• Kowey PR, Roy D, Pratt CM, et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery [abstract 2860]. Circulation2007;116:II_636-7
   Google Scholar
• Blaauw Y, Gogelein H, Teileman RG, et al. ‘Early’ class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation2004;110:1717-24
   PubMed Web of Science ®Google Scholar
• De Haan S, Greiser M, Harks E, et al. AVE0118, blocker of the transient outward current (Ito) and ultrarapid delayed rectifier current (IKur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation2006;114:1234-42
   PubMed Web of Science ®Google Scholar
• Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol2006;47:123-32
   PubMed Web of Science ®Google Scholar
• Benito B, Brugada R, Brugada J, Brugada P. Brugada syndrome. Prog Cardiovasc Dis2008;51:1-22
   PubMed Web of Science ®Google Scholar
• Lofberg L, Jacobson I, Carlsson L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace2006;8:549-57
   PubMed Web of Science ®Google Scholar
• Crijns HJ, Van Gelder IC, Walfridsson H, et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm2006;3:1321-31
   PubMed Web of Science ®Google Scholar
• Rahme M, Ungab GA, Wadhwa M, et al. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter. J Cardiovasc Pharmacol Ther2001;6:297-306
   PubMedGoogle Scholar
• Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current IK,ACh is constitutively active in patients with chronic atrial fibrillation. Circulation2005;112:3697-706
   PubMed Web of Science ®Google Scholar
• Voigt N, Maguy A, Yeh YH, et al. Changes in IK,ACh single-channel activity with atrial tachycardia remodeling in canine atrial cardiomyocytes. Cardiovasc Res2008;77:35-43
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation2004;110:904-10
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results form the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation2007;116:1647-52
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation2007;116:1449-57
   PubMed Web of Science ®Google Scholar
• Doctor's Guide Channels. DGNews: angina pectoris/MI. FDA approves ranolazine as first-line treatment of chronic angina. 6 November 2008. Available from: http://www.docguide.com/news/content.nsf/news/852571020057CCF6852574F9007A0CE6
   Google Scholar
• Lifescience online. Scientific-pipeline-regulatory >cardiovascular. FDA approves Ranexa® for first line anti anginal use and adds new claims for reduction of ventricular arrhythmias, bradycardia, new atrial fibrillation and HbA1c. 6 November 2008. Available from: http://www.lifescience-online.com/FDA_Approves_Ranexa_R__for_First_Line_Anti_Anginal,12655.html?portalPage=Lifescience+Today.News
   Google Scholar
• Savelieva I, Camm AJ. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace2004;5:S5-19
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace2008;10:647-65
   PubMed Web of Science ®Google Scholar
• Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J2006;27:512-18
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation1999;100:376-80
   PubMed Web of Science ®Google Scholar
• Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol2005;45:1832-9
   PubMed Web of Science ®Google Scholar
• Disertori M, Latini R, Delise P, et al. The role of valsartan in the prevention of atrial fibrillation recurrence: the GISSI-AF results. Circulation2008;118:S827
   Google Scholar
• Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol2003;92:1379-83
   PubMed Web of Science ®Google Scholar
• Amar D, Zhang H, Heerdt PM, et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest2005;128:3421-27
   PubMed Web of Science ®Google Scholar
• Ozaydin M, Dogan A, Varol E, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology2007;107:117-21
   PubMed Web of Science ®Google Scholar
• Patti G, Chello M, Candura M, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia after Cardiac Surgery). Circulation2006;114:1455-61
   PubMed Web of Science ®Google Scholar
• Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation2006;114:1703-12
   PubMed Web of Science ®Google Scholar
• Guerra JM, Everett TH IV, Lee KW, et al. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation2006;114:110-18
   PubMed Web of Science ®Google Scholar
• Bang H, Dyerberg J, Nielsen A. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet1971;1:1143-5
   PubMed Web of Science ®Google Scholar
• Billman G, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega3 fatty acids. Proc Natl Acad Sci USA1994;91:4427-30
   PubMed Web of Science ®Google Scholar
• Xiao YF, Wright SN, Wang GK, et al. Fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na+ channel. Proc Natl Acad Sci USA1998;95:2680-5
   PubMed Web of Science ®Google Scholar
• Xiao YF, Gomez AM, Morgan JP, et al. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA1997;94:4182-7
   PubMed Web of Science ®Google Scholar
• Guizy M, Arias C, David M, et al. Omega-3 and omega-6 polyunsaturated fatty acids block HERG channels. Am J Physiol Cell Physiol2005;289:C1251-60
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation2004;110:368-73
   PubMed Web of Science ®Google Scholar
• Brouwer IA, Heeringa J, Geleijnse JM, et al. Intake of very long chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J2006;151:857-62
   PubMed Web of Science ®Google Scholar
• Frost L, Vestergaard P. N-3 fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr2005;81:50-4
   PubMed Web of Science ®Google Scholar
• Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation2002;105:1077-81
   PubMed Web of Science ®Google Scholar
• Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol2003;42:185-97
   PubMed Web of Science ®Google Scholar
• Cheema A, Dong J, Dalal D, et al. Long-term safety and efficacy of circumferential ablation with pulmonary vein isolation. J Cardiovasc Electrophysiol2006;17:1080-5
   PubMed Web of Science ®Google Scholar
• Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation versus antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA2005;293:2634-40
   PubMed Web of Science ®Google Scholar
• Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med2006;354:934-41
   PubMed Web of Science ®Google Scholar
• Calkins H, Brugada J, Packer DL et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm2007;4:816-61
   PubMed Web of Science ®Google Scholar